Fetal exposure to isotretinoin—An international problem
Isotretinoin is a known teratogen. Pregnancy prevention programs aimed at minimizing isotretinoin exposure in pregnancy have been implemented in North America with limited success. To compare the management of fetal risk of isotretinoin in three countries, including information given to women, imple...
Gespeichert in:
| Veröffentlicht in: | Reproductive toxicology (Elmsford, N.Y.) N.Y.), 2008, Vol.25 (1), p.124-128 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 128 |
|---|---|
| container_issue | 1 |
| container_start_page | 124 |
| container_title | Reproductive toxicology (Elmsford, N.Y.) |
| container_volume | 25 |
| creator | Garcia-Bournissen, Facundo Tsur, Lilach Goldstein, Lee H. Staroselsky, Arthur Avner, Marina Asrar, Farhan Berkovitch, Matitiahu Straface, Gianluca Koren, Gideon De Santis, Marco |
| description | Isotretinoin is a known teratogen. Pregnancy prevention programs aimed at minimizing isotretinoin exposure in pregnancy have been implemented in North America with limited success.
To compare the management of fetal risk of isotretinoin in three countries, including information given to women, implementation of contraceptive methods, and pregnancy outcomes.
Pregnant women exposed to isotretinoin who called teratogen information services (TIS) in Israel, Italy and Canada between July 1998 and October 2006 were interviewed at the time of initial consultation and after the expected day of delivery.
Fifty-three pregnant women exposed to isotretinoin contacted the TIS. Only 41% reported using a birth control method. Just one patient reported using two different forms.
Forty-five percent of exposed pregnancies were terminated before delivery and 22% delivered healthy babies. Two babies were born with malformations.
Since isotretinoin-exposed pregnancies still occur, there is a need for more effective strategies, which should take into account the cultural differences. |
| doi_str_mv | 10.1016/j.reprotox.2007.10.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20655952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0890623807002845</els_id><sourcerecordid>20655952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-2ecf86e7639ceb32f39df0ad47f693904ba890e2fac170ab529eb382748090da3</originalsourceid><addsrcrecordid>eNqFkM9KAzEQh4MotlZfofSit11ns3-yuVmKVaHgRc8hm52FlG1Sk6zUmw_hE_okprTi0dPA8M38fnyETDNIM8iq23XqcOtssLuUArC4TAHKEzLOapYnGYP6lIyh5pBUNK9H5ML7NQAUjLNzMspqYCzL6ZjwJQbZz3C3tX5wOAt2pr0NDoM2Vpvvz6-5mWkT0BkZtDWRjbFNj5tLctbJ3uPVcU7I6_L-ZfGYrJ4fnhbzVaIKykJCUXV1hazKucImp13O2w5kW7Cu4jmHopGxJdJOqthaNiXlEaspK2rg0Mp8Qm4Of2Pu24A-iI32CvteGrSDFxSqsuQljWB1AJWz3jvsxNbpjXQfIgOxlybW4lea2Evb76O0eDg9JgzNBtu_s6OlCFwfAemV7DsnjdL-j-OcF3tyQu4OHEYf7xqd8EqjUdhqhyqI1ur_uvwARvWP4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20655952</pqid></control><display><type>article</type><title>Fetal exposure to isotretinoin—An international problem</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Garcia-Bournissen, Facundo ; Tsur, Lilach ; Goldstein, Lee H. ; Staroselsky, Arthur ; Avner, Marina ; Asrar, Farhan ; Berkovitch, Matitiahu ; Straface, Gianluca ; Koren, Gideon ; De Santis, Marco</creator><creatorcontrib>Garcia-Bournissen, Facundo ; Tsur, Lilach ; Goldstein, Lee H. ; Staroselsky, Arthur ; Avner, Marina ; Asrar, Farhan ; Berkovitch, Matitiahu ; Straface, Gianluca ; Koren, Gideon ; De Santis, Marco</creatorcontrib><description>Isotretinoin is a known teratogen. Pregnancy prevention programs aimed at minimizing isotretinoin exposure in pregnancy have been implemented in North America with limited success.
To compare the management of fetal risk of isotretinoin in three countries, including information given to women, implementation of contraceptive methods, and pregnancy outcomes.
Pregnant women exposed to isotretinoin who called teratogen information services (TIS) in Israel, Italy and Canada between July 1998 and October 2006 were interviewed at the time of initial consultation and after the expected day of delivery.
Fifty-three pregnant women exposed to isotretinoin contacted the TIS. Only 41% reported using a birth control method. Just one patient reported using two different forms.
Forty-five percent of exposed pregnancies were terminated before delivery and 22% delivered healthy babies. Two babies were born with malformations.
Since isotretinoin-exposed pregnancies still occur, there is a need for more effective strategies, which should take into account the cultural differences.</description><identifier>ISSN: 0890-6238</identifier><identifier>EISSN: 1873-1708</identifier><identifier>DOI: 10.1016/j.reprotox.2007.10.005</identifier><identifier>PMID: 18077132</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Abnormalities, Drug-Induced - etiology ; Abnormalities, Drug-Induced - prevention & control ; Abortion, Therapeutic ; Adult ; Biological and medical sciences ; Canada ; Contraception ; Dermatologic Agents - toxicity ; Drug Information Services ; Embryology: invertebrates and vertebrates. Teratology ; Female ; Fetus - drug effects ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Global Health ; Guideline Adherence ; Health Knowledge, Attitudes, Practice ; Humans ; Infant, Newborn ; Isotretinoin ; Isotretinoin - toxicity ; Israel ; Italy ; Live Birth ; Medical sciences ; Patient Education as Topic ; Practice Guidelines as Topic ; Pregnancy ; Pregnancy Trimester, First ; Prevention programs ; Surveys and Questionnaires ; Teratogen information service ; Teratogens ; Teratology. Teratogens ; Toxicology</subject><ispartof>Reproductive toxicology (Elmsford, N.Y.), 2008, Vol.25 (1), p.124-128</ispartof><rights>2007 Elsevier Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-2ecf86e7639ceb32f39df0ad47f693904ba890e2fac170ab529eb382748090da3</citedby><cites>FETCH-LOGICAL-c427t-2ecf86e7639ceb32f39df0ad47f693904ba890e2fac170ab529eb382748090da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.reprotox.2007.10.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,4025,27928,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19994771$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18077132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garcia-Bournissen, Facundo</creatorcontrib><creatorcontrib>Tsur, Lilach</creatorcontrib><creatorcontrib>Goldstein, Lee H.</creatorcontrib><creatorcontrib>Staroselsky, Arthur</creatorcontrib><creatorcontrib>Avner, Marina</creatorcontrib><creatorcontrib>Asrar, Farhan</creatorcontrib><creatorcontrib>Berkovitch, Matitiahu</creatorcontrib><creatorcontrib>Straface, Gianluca</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>De Santis, Marco</creatorcontrib><title>Fetal exposure to isotretinoin—An international problem</title><title>Reproductive toxicology (Elmsford, N.Y.)</title><addtitle>Reprod Toxicol</addtitle><description>Isotretinoin is a known teratogen. Pregnancy prevention programs aimed at minimizing isotretinoin exposure in pregnancy have been implemented in North America with limited success.
To compare the management of fetal risk of isotretinoin in three countries, including information given to women, implementation of contraceptive methods, and pregnancy outcomes.
Pregnant women exposed to isotretinoin who called teratogen information services (TIS) in Israel, Italy and Canada between July 1998 and October 2006 were interviewed at the time of initial consultation and after the expected day of delivery.
Fifty-three pregnant women exposed to isotretinoin contacted the TIS. Only 41% reported using a birth control method. Just one patient reported using two different forms.
Forty-five percent of exposed pregnancies were terminated before delivery and 22% delivered healthy babies. Two babies were born with malformations.
Since isotretinoin-exposed pregnancies still occur, there is a need for more effective strategies, which should take into account the cultural differences.</description><subject>Abnormalities, Drug-Induced - etiology</subject><subject>Abnormalities, Drug-Induced - prevention & control</subject><subject>Abortion, Therapeutic</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Canada</subject><subject>Contraception</subject><subject>Dermatologic Agents - toxicity</subject><subject>Drug Information Services</subject><subject>Embryology: invertebrates and vertebrates. Teratology</subject><subject>Female</subject><subject>Fetus - drug effects</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Global Health</subject><subject>Guideline Adherence</subject><subject>Health Knowledge, Attitudes, Practice</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Isotretinoin</subject><subject>Isotretinoin - toxicity</subject><subject>Israel</subject><subject>Italy</subject><subject>Live Birth</subject><subject>Medical sciences</subject><subject>Patient Education as Topic</subject><subject>Practice Guidelines as Topic</subject><subject>Pregnancy</subject><subject>Pregnancy Trimester, First</subject><subject>Prevention programs</subject><subject>Surveys and Questionnaires</subject><subject>Teratogen information service</subject><subject>Teratogens</subject><subject>Teratology. Teratogens</subject><subject>Toxicology</subject><issn>0890-6238</issn><issn>1873-1708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9KAzEQh4MotlZfofSit11ns3-yuVmKVaHgRc8hm52FlG1Sk6zUmw_hE_okprTi0dPA8M38fnyETDNIM8iq23XqcOtssLuUArC4TAHKEzLOapYnGYP6lIyh5pBUNK9H5ML7NQAUjLNzMspqYCzL6ZjwJQbZz3C3tX5wOAt2pr0NDoM2Vpvvz6-5mWkT0BkZtDWRjbFNj5tLctbJ3uPVcU7I6_L-ZfGYrJ4fnhbzVaIKykJCUXV1hazKucImp13O2w5kW7Cu4jmHopGxJdJOqthaNiXlEaspK2rg0Mp8Qm4Of2Pu24A-iI32CvteGrSDFxSqsuQljWB1AJWz3jvsxNbpjXQfIgOxlybW4lea2Evb76O0eDg9JgzNBtu_s6OlCFwfAemV7DsnjdL-j-OcF3tyQu4OHEYf7xqd8EqjUdhqhyqI1ur_uvwARvWP4w</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Garcia-Bournissen, Facundo</creator><creator>Tsur, Lilach</creator><creator>Goldstein, Lee H.</creator><creator>Staroselsky, Arthur</creator><creator>Avner, Marina</creator><creator>Asrar, Farhan</creator><creator>Berkovitch, Matitiahu</creator><creator>Straface, Gianluca</creator><creator>Koren, Gideon</creator><creator>De Santis, Marco</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>2008</creationdate><title>Fetal exposure to isotretinoin—An international problem</title><author>Garcia-Bournissen, Facundo ; Tsur, Lilach ; Goldstein, Lee H. ; Staroselsky, Arthur ; Avner, Marina ; Asrar, Farhan ; Berkovitch, Matitiahu ; Straface, Gianluca ; Koren, Gideon ; De Santis, Marco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-2ecf86e7639ceb32f39df0ad47f693904ba890e2fac170ab529eb382748090da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Abnormalities, Drug-Induced - etiology</topic><topic>Abnormalities, Drug-Induced - prevention & control</topic><topic>Abortion, Therapeutic</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Canada</topic><topic>Contraception</topic><topic>Dermatologic Agents - toxicity</topic><topic>Drug Information Services</topic><topic>Embryology: invertebrates and vertebrates. Teratology</topic><topic>Female</topic><topic>Fetus - drug effects</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Global Health</topic><topic>Guideline Adherence</topic><topic>Health Knowledge, Attitudes, Practice</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Isotretinoin</topic><topic>Isotretinoin - toxicity</topic><topic>Israel</topic><topic>Italy</topic><topic>Live Birth</topic><topic>Medical sciences</topic><topic>Patient Education as Topic</topic><topic>Practice Guidelines as Topic</topic><topic>Pregnancy</topic><topic>Pregnancy Trimester, First</topic><topic>Prevention programs</topic><topic>Surveys and Questionnaires</topic><topic>Teratogen information service</topic><topic>Teratogens</topic><topic>Teratology. Teratogens</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garcia-Bournissen, Facundo</creatorcontrib><creatorcontrib>Tsur, Lilach</creatorcontrib><creatorcontrib>Goldstein, Lee H.</creatorcontrib><creatorcontrib>Staroselsky, Arthur</creatorcontrib><creatorcontrib>Avner, Marina</creatorcontrib><creatorcontrib>Asrar, Farhan</creatorcontrib><creatorcontrib>Berkovitch, Matitiahu</creatorcontrib><creatorcontrib>Straface, Gianluca</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>De Santis, Marco</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Reproductive toxicology (Elmsford, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garcia-Bournissen, Facundo</au><au>Tsur, Lilach</au><au>Goldstein, Lee H.</au><au>Staroselsky, Arthur</au><au>Avner, Marina</au><au>Asrar, Farhan</au><au>Berkovitch, Matitiahu</au><au>Straface, Gianluca</au><au>Koren, Gideon</au><au>De Santis, Marco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fetal exposure to isotretinoin—An international problem</atitle><jtitle>Reproductive toxicology (Elmsford, N.Y.)</jtitle><addtitle>Reprod Toxicol</addtitle><date>2008</date><risdate>2008</risdate><volume>25</volume><issue>1</issue><spage>124</spage><epage>128</epage><pages>124-128</pages><issn>0890-6238</issn><eissn>1873-1708</eissn><abstract>Isotretinoin is a known teratogen. Pregnancy prevention programs aimed at minimizing isotretinoin exposure in pregnancy have been implemented in North America with limited success.
To compare the management of fetal risk of isotretinoin in three countries, including information given to women, implementation of contraceptive methods, and pregnancy outcomes.
Pregnant women exposed to isotretinoin who called teratogen information services (TIS) in Israel, Italy and Canada between July 1998 and October 2006 were interviewed at the time of initial consultation and after the expected day of delivery.
Fifty-three pregnant women exposed to isotretinoin contacted the TIS. Only 41% reported using a birth control method. Just one patient reported using two different forms.
Forty-five percent of exposed pregnancies were terminated before delivery and 22% delivered healthy babies. Two babies were born with malformations.
Since isotretinoin-exposed pregnancies still occur, there is a need for more effective strategies, which should take into account the cultural differences.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>18077132</pmid><doi>10.1016/j.reprotox.2007.10.005</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-6238 |
| ispartof | Reproductive toxicology (Elmsford, N.Y.), 2008, Vol.25 (1), p.124-128 |
| issn | 0890-6238 1873-1708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20655952 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Abnormalities, Drug-Induced - etiology Abnormalities, Drug-Induced - prevention & control Abortion, Therapeutic Adult Biological and medical sciences Canada Contraception Dermatologic Agents - toxicity Drug Information Services Embryology: invertebrates and vertebrates. Teratology Female Fetus - drug effects Follow-Up Studies Fundamental and applied biological sciences. Psychology Global Health Guideline Adherence Health Knowledge, Attitudes, Practice Humans Infant, Newborn Isotretinoin Isotretinoin - toxicity Israel Italy Live Birth Medical sciences Patient Education as Topic Practice Guidelines as Topic Pregnancy Pregnancy Trimester, First Prevention programs Surveys and Questionnaires Teratogen information service Teratogens Teratology. Teratogens Toxicology |
| title | Fetal exposure to isotretinoin—An international problem |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T22%3A38%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fetal%20exposure%20to%20isotretinoin%E2%80%94An%20international%20problem&rft.jtitle=Reproductive%20toxicology%20(Elmsford,%20N.Y.)&rft.au=Garcia-Bournissen,%20Facundo&rft.date=2008&rft.volume=25&rft.issue=1&rft.spage=124&rft.epage=128&rft.pages=124-128&rft.issn=0890-6238&rft.eissn=1873-1708&rft_id=info:doi/10.1016/j.reprotox.2007.10.005&rft_dat=%3Cproquest_cross%3E20655952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20655952&rft_id=info:pmid/18077132&rft_els_id=S0890623807002845&rfr_iscdi=true |